MREO Stock Forecast & Price Target

Mereo BioPharma Group is attractive because alvelestat addresses a large unmet need in severe AATD lung disease, where liver-focused antisense approaches do not protect the lungs, and its earlier data showed a 48% reduction in moderate/severe exacerbations and a 36% decline in annualized exacerbation rate versus placebo across ATLANTa and ASTRAEUS. The option agreement with Sentynl externally validates the program, could fund Phase III development with $40M, and may unlock up to $435M in milestones plus double-digit U.S. royalties while preserving ex-U.S. rights for Mereo. The outlook is further supported by setrusumab’s ongoing regulatory discussions and the broader late-stage rare-disease portfolio, which targets high-need markets with meaningful clinical differentiation.

Mereo BioPharma Group is burdened by a weak setrusumab efficacy profile, as the Phase 3 ORBIT trial missed both the primary fracture endpoint and the key secondary fracture endpoint despite a 159-patient randomized design. Although bone mineral density, pain, and daily-function measures improved, those findings did not translate into statistically significant fracture reduction, and 19.5% of patients met rescue criteria at 12 months, highlighting persistent disease burden and possible treatment failure in more severe Type III/IV patients. The company also faces typical development-stage biotech risks, including the need for additional funding, uncertain milestone payments from Ultragenyx, and exposure to regulatory and commercialization uncertainty across its rare-disease pipeline.